HDL Therapeutics is a commercial-stage biotechnology company with an FDA approved therapy for reducing coronary atheroma in a rare cardiovascular disease.
Disrupting the Industry
HDL Therapeutics represents the union of some of the top talent in the pharmaceutical, biotechnology, and medical device industries. Co-founders Michael Matin, CEO and Chairman of the Board, and Dr. Bryan Brewer, Chief Scientific Officer, bring decades of experience with large pharmaceutical organizations, blockbuster product launches, and breakthrough research.
Vision / Mission
We are working on the cutting edge of science with future therapies for cardiovascular, neurodegenerative, autoimmune, viral and peripheral vascular diseases.
Our mission is to fill a critical gap in treatment options for patients with severe atherosclerotic disease through our breakthrough therapy that harness the power of HDL to reverse—rather than just manage—atherosclerosis.